ArticleMedComm2026

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD-1 Inhibitor and Niraparib in GErm-Line-mutAted Metastatic Breast Cancer.

Jian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.